David Ricks, Eli Lilly CEO (David Paul Morris/Bloomberg via Getty Images)
Eli Lilly shepherds its $1.1B contender through another PhIII challenge on the way to the FDA
Just 6 days after Eli Lilly execs ID’d its $1.1 billion atopic dermatitis drug lebrikizumab as one of its top late-stage drug candidates, the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
